We are advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. We have three internally-developed late-stage clinical drug candidates, four marketed products in China and one marketed product in the U.S.
Explore our interactive pipeline to discover our extensive clinical portfolio, spanning a broad range of solid tumor and hematological malignancy indications. Find out more about our drugs and clinical trials in your target indications.